Form 4: Herbalife CEO Gratziani Granted 215,033 Stock Appreciation Rights

Herbalife's CEO, Stephan Paulo Gratziani, was granted 215,033 Stock Appreciation Rights with a $10.51 exercise price, vesting over three years.

Summary

• Stephan Paulo Gratziani, Chief Executive Officer of Herbalife Ltd. (HLF), was granted 215,033 Stock Appreciation Rights (SARs).
• The SARs have an exercise price of $10.51 per share.
• These SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029.
• Vesting is contingent upon Gratziani's continued service to the company through each respective vesting date.
• The SARs were granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan and are set to expire on February 25, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive incentive practices aimed at long-term value creation and executive retention.

Positives

• The grant of Stock Appreciation Rights aligns the CEO's incentives with shareholder value creation, as SARs only gain value if the stock price increases above the exercise price of $10.51.
• The multi-year vesting schedule, extending to February 2029, promotes long-term retention of a key executive.

Future Outlook

The vesting schedule of the SARs, extending to February 2029, indicates an expectation of continued service from the CEO and a long-term focus on increasing shareholder value.

Industry Context

StockSavvy.ai notes that granting equity-based compensation like SARs to key executives is a standard practice across various industries, particularly in consumer goods and direct selling, to align management's interests with long-term company performance and shareholder returns. This practice is common for retaining top talent and incentivizing growth.

Comparison to Industry Standards

• The grant of SARs with a multi-year vesting schedule is a common executive compensation tool, comparable to practices at companies like Nu Skin Enterprises (NUS) or USANA Health Sciences (USNA), which also utilize performance-based equity awards to incentivize leadership.
• The specific exercise price of $10.51 would typically be set at or above the market price on the grant date, a standard practice to ensure the executive benefits only from future stock appreciation.

Related Party Transactions

• Grant of 215,033 Stock Appreciation Rights to Stephan Paulo Gratziani, the Chief Executive Officer, under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the CEO's incentives lead to stock price appreciation.
• CEO (Management): Incentivized for long-term performance and retention.

Next Steps

• The SARs will vest in one-third increments on February 25, 2027, February 25, 2028, and February 25, 2029, subject to continued service.
• The CEO may exercise the vested SARs at any time before the expiration date of February 25, 2036, assuming the stock price is above the exercise price.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant, which is a standard corporate governance practice. It does not contain information that would fundamentally alter the investment thesis for Herbalife. The grant aligns executive incentives with shareholder interests, which is generally positive, but it's not a catalyst for a "buy" or "sell" recommendation on its own. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Herbalife, HLF, Stephan Paulo Gratziani, CEO, Stock Appreciation Rights, SARs, equity compensation, executive compensation, Form 4, insider transaction, stock incentive plan